1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Rheumatology Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Rheumatology Therapeutics Market Revenue and Volume, by Drug Type
8.1.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Corticosteroids
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Targeted Synthetic DMARDs / JAK Inhibitors
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Uric-Acid-Lowering Agents (for gout)
8.1.5.1. Market Revenue and Volume Forecast
9.1. Rheumatology Therapeutics Market Revenue and Volume, by Disease Indication
9.1.1. Rheumatoid Arthritis (RA)
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Osteoarthritis (OA)
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Gout
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Ankylosing Spondylitis (AS)
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Lupus (Systemic Lupus Erythematosus)
9.1.5.1. Market Revenue and Volume Forecast
10.1. Rheumatology Therapeutics Market Revenue and Volume, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Injectable / Infusion
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Topical
10.1.3.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Drug Type
11.1.2. Market Revenue and Volume Forecast, by Disease Indication
11.1.3. Market Revenue and Volume Forecast, by Route of Administration
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Drug Type
11.1.4.2. Market Revenue and Volume Forecast, by Disease Indication
11.1.4.3. Market Revenue and Volume Forecast, by Route of Administration
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Drug Type
11.1.5.2. Market Revenue and Volume Forecast, by Disease Indication
11.1.5.3. Market Revenue and Volume Forecast, by Route of Administration
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Drug Type
11.2.2. Market Revenue and Volume Forecast, by Disease Indication
11.2.3. Market Revenue and Volume Forecast, by Route of Administration
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Drug Type
11.2.4.2. Market Revenue and Volume Forecast, by Disease Indication
11.2.4.3. Market Revenue and Volume Forecast, by Route of Administration
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Drug Type
11.2.5.2. Market Revenue and Volume Forecast, by Disease Indication
11.2.5.3. Market Revenue and Volume Forecast, by Route of Administration
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Drug Type
11.2.6.2. Market Revenue and Volume Forecast, by Disease Indication
11.2.6.3. Market Revenue and Volume Forecast, by Route of Administration
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Drug Type
11.2.7.2. Market Revenue and Volume Forecast, by Disease Indication
11.2.7.3. Market Revenue and Volume Forecast, by Route of Administration
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Drug Type
11.3.2. Market Revenue and Volume Forecast, by Disease Indication
11.3.3. Market Revenue and Volume Forecast, by Route of Administration
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Drug Type
11.3.4.2. Market Revenue and Volume Forecast, by Disease Indication
11.3.4.3. Market Revenue and Volume Forecast, by Route of Administration
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Drug Type
11.3.5.2. Market Revenue and Volume Forecast, by Disease Indication
11.3.5.3. Market Revenue and Volume Forecast, by Route of Administration
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Drug Type
11.3.6.2. Market Revenue and Volume Forecast, by Disease Indication
11.3.6.3. Market Revenue and Volume Forecast, by Route of Administration
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Drug Type
11.3.7.2. Market Revenue and Volume Forecast, by Disease Indication
11.3.7.3. Market Revenue and Volume Forecast, by Route of Administration
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Drug Type
11.4.2. Market Revenue and Volume Forecast, by Disease Indication
11.4.3. Market Revenue and Volume Forecast, by Route of Administration
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Drug Type
11.4.4.2. Market Revenue and Volume Forecast, by Disease Indication
11.4.4.3. Market Revenue and Volume Forecast, by Route of Administration
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Drug Type
11.4.5.2. Market Revenue and Volume Forecast, by Disease Indication
11.4.5.3. Market Revenue and Volume Forecast, by Route of Administration
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Drug Type
11.4.6.2. Market Revenue and Volume Forecast, by Disease Indication
11.4.6.3. Market Revenue and Volume Forecast, by Route of Administration
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Drug Type
11.4.7.2. Market Revenue and Volume Forecast, by Disease Indication
11.4.7.3. Market Revenue and Volume Forecast, by Route of Administration
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Drug Type
11.5.2. Market Revenue and Volume Forecast, by Disease Indication
11.5.3. Market Revenue and Volume Forecast, by Route of Administration
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Drug Type
11.5.4.2. Market Revenue and Volume Forecast, by Disease Indication
11.5.4.3. Market Revenue and Volume Forecast, by Route of Administration
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Drug Type
11.5.5.2. Market Revenue and Volume Forecast, by Disease Indication
11.5.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.1. Johnson & Johnson
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Amgen Inc
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bristol-Myers Squibb Company
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Novartis AG
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. UCB S.A.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Eli Lilly and Company
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Gilead Sciences, Inc
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Takeda Pharmaceutical Company
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Roche Holding AG
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. AstraZeneca plc
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
